Published • loading... • Updated
ABBVIE: Positive Results From Phase 3 Study for Multiple Myeloma Drug
Summary by news4health.gr
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
AbbVie announced positive results from the Phase 3 CERVINO study, showing that etentamig significantly improved response rate and progression-free survival in…More...
·Greece
Read Full Article
The investigational product achieved an overall response rate of 74% and a 60% reduction in the risk of disease progression or death compared to standard available therapies selected by the investigator. AbbVie announced positive results from the Phase 3 CERVINO study, which is evaluating etentamig, an investigational bispecific antibody that activates BCMA × CD3 T cells, against standard available therapies (SAT) in patients with relapsed/refra…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
